Treatment of Staphylococcus Aureus Colonization in Hand Eczema

Inclusion Criteria: * Male or female subjects at least 18 years of age with a clear diagnosis of moderate-to-severe hand or hand/foot dermatitis. * Subjects must be in general good health as confirmed by a medical history. * Subjects must be capable of understanding and willing to provide a signed and dated written voluntary informed consent before any protocol specific procedures are performed. * At the Baseline Visit, Subjects must have a Physician's Global Assessment (PGA) of at least 3 (moderate severity). * Subject must be willing and able to participate in the study as an outpatient, making frequent visits to the study center during the treatment and follow-up period periods and comply with all study requirements. * If a subject is a female of childbearing potential she must have a negative urine pregnancy test prior to study treatment initiation and must agree to use an approved method of birth control during the study period (barrier, oral, injection, intrauterine). NOTE: Post-menopausal (amenorrhea for at least one year) or surgically sterile (tubal ligation and/or hysterectomy) females are categorized as non-childbearing potential. Exclusion Criteria: * Non-English speaking subjects * Females who are pregnant, breast feeding, or attempting to conceive. * Subjects with a history of known or suspected intolerance to any of the excipients of retapamulin 1% ointment or clobetasol propionate 0.05% foam. * Subjects who have used any topical corticosteroids, topical antibiotics, topical immunosuppressants, other topical therapies (tar, calcineurin inhibitors), or phototherapy (PUVA, UVB) within eight weeks of the Baseline Visit. * Subjects who have used any systemic corticosteroids, systemic antibiotics, or systemic immunosuppressants therapies within eight weeks of the Baseline Visit. * Subjects with any overt signs of skin atrophy, telangiectasias, and/or striae in the target area(s). * Subjects with any active skin malignancy. * Subjects requiring the use of medications known to alter the course of atopic dermatitis during the study period. * Subjects who are currently participating in or, within the previous 28 days, have participated in another study for the treatment for atopic dermatitis.